Guillain-Barre Syndrome Market Size

Global Guillain-Barre Syndrome Market Overview

Guillain-Barre Syndrome Market Size was valued at USD 0.23 Billion in 2023. The Global Guillain-Barre Syndrome industry is projected to grow from USD 0.311 Billion in 2024 to USD 0.60 Billion by 2032, exhibiting a compound annual growth rate (CAGR) of 5.36% during the forecast period (2024 - 2032).

Guillain-Barre Syndrome is a rare immune system disorder. In this medical condition, the patients’ immune system attacks their nervous system. The causative agents of the Guillain-Barre Syndrome are unknown. However, it is illuminated that the disease is often accompanied by infections including respiratory infection and stomach flu. The weakness of legs, difficulty in breathing, low or high blood pressure, difficulty with eye or facial movements is some of the common symptoms of the Guillain-Barre Syndrome.

The increasing prevalence of the Guillain-Barre Syndrome is expected to be one of the major drivers for the market growth during the forecast period. According to a study published by the PLOS One Journal in 2017, Guillain-Barre Syndrome is amongst some of the most common types of serious acute paralytic neuropathy. Moreover, it was estimated that about 100,000 new cases of the disease are reported, annually across the globe.

Additionally, growing geriatric population and increasing prevalence of chikungunya boost the market growth. According to the World Health Organization in 2016, about 349 936 suspected and 146,914 laboratory confirmed cases of chikungunya were reported to the PAHO regional office. Countries that reported most of the cases were Brazil (265,000 suspected cases), Bolivia, and Colombia (19,000 suspected cases). However, lack of awareness for the disease, absence of any definitive treatment, and low per capita healthcare expenditures in the middle- and low-income countries are estimated to restrain the market growth during the projected period.

October 2023 saw the oncology firm Servier announce that in relation to adult patients who have myelodysplastic syndromes (MDS) with IDH1 mutation, TIBSOVO® (ivosidenib tablets) have been accepted by the USFDA for use when they regress or do not respond to treatment. It is the first targeted therapy to be FDA-approved for patients with R/R MDS in this molecularly defined subtype and is the fifth indication for IDH1 mutated cancer. The approval was based on a pivotal Phase 1 open-label study conducted in IDH1-mutated R/R MDS patients (n=18) that demonstrated a complete remission rate of 38.9% and an objective response rate (ORR) of 83.3% among those who received TIBSOVO.

YUSIMRY™ goes on sale at $995 per box of two auto-injectors each containing 40 mg/0.8 mL, which is over eighty-five percent less than wholesale acquisition cost per box of Humira®’s two pens estimated at $6,922; what distinguishes Coherus’s new autoinjector from others is its exclusive nonastringent citrate-free formulation featuring needle size twenty-nine gauge; further YUSIMRY was cleared by USFDA only in 2021 as such makes it an anti-tumor necrosis factor (“TNF”) blocker classified as indicated for the reduction of signs and symptoms associated with rheumatoid arthritis (RA), juvenile idiopathic arthritis (JIA), psoriatic arthritis (PsA), and ankylosing spondylitis and Crohn’s disease, ulcerative colitis, plaque psoriasis and hidradenitis suppurativa.

Another CAR t-cell therapy alternative has come up in advanced multiple myeloma. This treatment was approved by the FDA on February 28th for adult patients with relapsed or refractory multiple myeloma. Moreover, cilta-cel also known as ciltacabtagene autoleucel may be given to these individuals under this approval following four or more lines of previous therapies including three major classes of drugs used to treat multiple myelomas like immunomodulating agent, proteasome inhibitors and anti-CD38 monoclonal antibodies.

Guillain-Barre Syndrome Market Segment Insights

The Guillain-Barre Syndrome market is segmented on the basis of type, diagnosis, treatment, and end-user.

Guillain-Barre Syndrome Type Insights

On the basis of type, the Guillain-Barre Syndrome Market is segmented into Acute Inflammatory Demyelinating Polyradiculoneuropathy (AIDP), Miller Fisher Syndrome (MFS), Acute Motor Axonal Neuropathy (AMAN), and others. 

Guillain-Barre Syndrome Diagnosis Insights

On the basis of diagnosis, the market is categorized into lumbar puncture, electromyography, nerve conduction studies, and others. The electromyography segment is sub-segmented into intramuscular electromyography, surface electromyography, and others. 

Guillain-Barre Syndrome Treatment Insights

On the basis of treatment, the market is segmented into plasmapheresis, medication, physical therapy, hydrotherapy, and others. The medication segment is sub-segmented into privigen intravenous, gammagard liquid injection, flebogamma DIF intravenous, bivigam intravenous, and others. 

Guillain-Barre Syndrome End-User Insights

On the basis of end-user, the market is segmented into hospitals and clinics, diagnostic centers, and others.

Guillain-Barre Syndrome Regional Insights

America dominates the Guillain-Barre Syndrome market in the presence of a well-developed healthcare sector and huge patient population. Moreover, the changing lifestyle and rising per capita healthcare expenditure fuel the market. Additionally, the presence of developed economies such as the U.S. and Canada within the region fuels the market growth.

Europe stands second in the Guillain-Barre Syndrome market. This can be attributed on the basis of availability of funds for research and a huge patient population. On a regional basis, Europe is segmented into Western Europe and Eastern Europe. Western Europe is estimated to lead the market while Eastern Europe is estimated to be the fastest growing region.

Asia Pacific is projected to be the fastest growing region for the Guillain-Barre syndrome market due to the presence of huge patient population and developing economies such as India and China within the region. Moreover, a growing healthcare sector and the growing government support boost the regional market for the Asia Pacific region.

On the other hand, the Middle East and Africa holds the least share of the global Guillain-Barre Syndrome Market. This can be attributed to the presence of poor economies, lack of healthcare services, and stringent government policies, especially in the African region. A majority of the regions of the Middle East and Africa is held by the Middle East owing to the increasing per capita healthcare expenditure by developed economies such as Dubai, Kuwait, and Saudi Arabia within the region.

Key Players in the Guillain-Barre Syndrome Market

The key players in the Guillain-Barre Syndrome Market are

• Grifols (Spain)


• Baxter (U.S.)


• CSL Behring (U.S.)


• Akari Therapeutics Plc (U.S.)


• ANNEXON, INC. (U.S.)


• Curavac (Europe)


• Hansa Medical (Sweden)


• Vitality Biopharma (U.S.)


• Covidien Limited (Republic of Ireland)


• Natus Medical Inc. (U.S.)


• Electrical Geodesics Inc. (U.S.)

Intended Audience

• Pharmaceutical Companies


• Biotechnological Institutes


• Government and Private Laboratories


• Research and Development (R&D) Companies


• Medical Research Laboratories


• Market Research and Consulting Service Providers